Pub. Date : 2021
PMID : 33841676
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | BACKGROUND: Crizotinib is a tyrosine kinase inhibitor (TKI) effective in ALK/ROS-1/c-MET positive non-small cell lung cancer (NSCLC) patients. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | However, the efficacy and safety of crizotinib plus bevacizumab in treating naive ALK/ROS-1/c-MET positive NSCLC patients have not been studied. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 4 | METHODS: In this open-label, single-arm, prospective observational study, locally advanced or metastatic ALK rearrangement/ROS-1 fusion/c-MET amplification NSCLC patients were treated with crizotinib (250 mg orally twice daily) and bevacizumab (7.5 mg/kg intravenous every three weeks) until disease progression or intolerant toxicity or death. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 5 | Our results suggested that crizotinib plus bevacizumab might be a promising treatment strategy in ALK/ROS-1/c-MET positive NSCLC patients. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |